Latest filings (excl ownership)
8-K
Shuttle Pharma Provides First Quarter 2024 Corporate Update
14 May 24
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
Other Events
29 Apr 24
8-K
Other Events
23 Apr 24
S-1
IPO registration
5 Apr 24
8-K
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
22 Mar 24
424B3
Prospectus supplement
22 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Shuttle Pharmaceuticals to Present at About Shuttle Pharmaceuticals
5 Mar 24
8-K
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
13 Feb 24
8-K
Entry into a Material Definitive Agreement
5 Feb 24
8-K
Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
8 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
19 Dec 23
8-K
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
11 Dec 23
8-K
Other Events
30 Nov 23
8-K
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
14 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
30 Oct 23
ARS
2022 FY
Annual report to shareholders
20 Oct 23
DEF 14A
Definitive proxy
20 Oct 23
8-K
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference
10 Oct 23
8-K
Entry into a Material Definitive Agreement
5 Oct 23
8-K
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
25 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Sep 23
424B3
Prospectus supplement
24 Aug 23
8-K
Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update
15 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial
3 Aug 23
DEF 14C
Information statement
16 Jun 23
PRE 14C
Preliminary information
5 Jun 23
8-K
Entry into a Material Definitive Agreement
5 Jun 23
8-K
Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update
26 May 23
10-Q
2023 Q1
Quarterly report
25 May 23
8-K
Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference
17 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
8-K
Entry into a Material Definitive Agreement
11 May 23
8-K
Departure of Directors or Certain Officers
3 May 23
8-K
Entry into a Material Definitive Agreement
22 Mar 23
10-K
2022 FY
Annual report
15 Mar 23
8-K
Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial
9 Mar 23
Latest ownership filings
4
Chris Senanayake
14 Mar 24
4
Hoek Michael Vander
8 Mar 24
4
Milton Brown
2 Jan 24
4
Bette Jacobs
20 Dec 23
SC 13G/A
AFH Holding & Advisory, LLC
18 Oct 23
4
Anatoly Dritschilo
18 Aug 23
SC 13G
AFH Holding & Advisory, LLC
30 May 23
SC 13G
AFH Holding & Advisory, LLC
6 Mar 23
4
Milton Brown
17 Feb 23
4
Steven M Richards
9 Jan 23
4
William Adkins
4 Jan 23
4
Milton Brown
4 Jan 23
4
Anatoly Dritschilo
3 Jan 23
4
Tyvin Rich
3 Jan 23
4
Mira Jung
3 Jan 23
4
Bette Jacobs
3 Jan 23
4
Peter Dritschilo
30 Dec 22
4
Hoek Michael Vander
30 Dec 22
3
Bette Jacobs
9 Nov 22
3
Milton Brown
9 Sep 22
3/A
Anatoly Dritschilo
8 Sep 22
3
Steven M Richards
7 Sep 22
3
Chris Senanayake
7 Sep 22
3
William Adkins
7 Sep 22
3
Tyvin Rich
7 Sep 22
3
Peter Dritschilo
7 Sep 22
3
Mira Jung
7 Sep 22
3
Hoek Michael Vander
7 Sep 22
3
Joshua Schafer
7 Sep 22
3
Anatoly Dritschilo
7 Sep 22